Literature DB >> 1384905

Phosphodiesterase inhibition in ventricular cardiomyocytes from guinea-pig hearts.

T Bethke1, W Meyer, W Schmitz, H Scholz, B Stein, K Thomas, H Wenzlaff.   

Abstract

1. The present study compared the cyclic nucleotide phosphodiesterase (PDE) activities in cardiomyocytes and ventricular cardiac tissue from guinea-pigs. The aim of the study was to determine whether PDE activities in ventricular tissue accurately reflect the isoenzymes present in cardiomyocytes. 2. In homogenates of cardiomyocytes and multicellular ventricular tissue, four distinct soluble PDE activities could be separated by DEAE-sepharose chromatography. 3. In multicellular cardiac tissue as well as in cardiomyocyte preparations, adenosine 3':5'-cyclic monophosphate (cyclic AMP) PDE isoenzymes I-IV were comparable in terms of substrate affinities, and inhibition or stimulation by guanosine 3':5'-cyclic monophosphate (cyclic GMP). However, in cardiomyocytes the Vmax values of PDE I-IV were lower by a factor of about 2 to 7 and the basal activities were lower by a factor of about 3 to 5 as compared to multicellular cardiac tissue. 4. To investigate whether the PDE I-IV activities were similarly inhibited by PDE inhibitors in both preparations, we studied the effects of 3-isobutyl-1-methylxanthine (IBMX), UD-CG 212 Cl (2-(4-hydroxy-phenyl)-5-(5-methyl-3-oxo-4, 5-dihydro-2H-6-pyridazinyl)benzimidazole HCl) and rolipram. UD-CG 212 Cl was a selective PDE III inhibitor in cardiomyocytes (IC50 0.3 mumol l-1) and in ventricular tissue (IC50 value 0.1 mumol l-1). Rolipram selectively inhibited PDE IV in cardiomyocytes (IC50 1.4 mumol ml-1) and in ventricular tissue (IC50 1.1 mumol l-1) whereas IBMX was a nonselective PDE inhibitor in both preparations.5. It is concluded that the PDE isoenzymes I-IV from multicellular ventricular tissue can be used as a representative system for investigating PDE inhibiting properties of PDE inhibitors in the myocardium since comparable PDE isoenzymes I-IV exist in guinea-pig ventricular cardiomyocytes and multicellular ventricular tissue.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1384905      PMCID: PMC1907617          DOI: 10.1111/j.1476-5381.1992.tb14474.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  24 in total

1.  Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.

Authors:  H von der Leyen; U Mende; W Meyer; J Neumann; M Nose; W Schmitz; H Scholz; J Starbatty; B Stein; H Wenzlaff
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-07       Impact factor: 3.000

2.  Effects of isomazole on force of contraction and phosphodiesterase isoenzymes I-IV in nonfailing and failing human hearts.

Authors:  T Bethke; A Klimkiewicz; C Kohl; H von der Leyen; H Mehl; U Mende; W Meyer; J Neumann; W Schmitz; H Scholz
Journal:  J Cardiovasc Pharmacol       Date:  1991-09       Impact factor: 3.105

Review 3.  Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors.

Authors:  J A Beavo; D H Reifsnyder
Journal:  Trends Pharmacol Sci       Date:  1990-04       Impact factor: 14.819

4.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

5.  Calcium tolerant ventricular myocytes prepared by preincubation in a "KB medium".

Authors:  G Isenberg; U Klockner
Journal:  Pflugers Arch       Date:  1982-10       Impact factor: 3.657

6.  Effects of the triazolopyrimidine trapidil on force of contraction, beating frequency and phosphodiesterase I--IV activity in guinea-pig hearts.

Authors:  T Bethke; H Mehl; W Meyer; W Schmitz; H Scholz; K Thomas; H Wenzlaff
Journal:  Arzneimittelforschung       Date:  1991-05

7.  Comparison of cyclic nucleotide phosphodiesterase isoenzymes in rat and rabbit ventricular myocardium: positive inotropic and phosphodiesterase inhibitory effects of Org 30029, milrinone and rolipram.

Authors:  M Shahid; C D Nicholson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-12       Impact factor: 3.000

8.  Differential antagonism by 1,3-dipropylxanthine-8-cyclopentylxanthine and 9-chloro-2-(2-furanyl)-5,6-dihydro-1,2,4-triazolo(1,5-c)quinazolin-5-im ine of the effects of adenosine derivatives in the presence of isoprenaline on contractile response and cyclic AMP content in cardiomyocytes. Evidence for the coexistence of A1- and A2-adenosine receptors on cardiomyocytes.

Authors:  N Behnke; W Müller; J Neumann; W Schmitz; H Scholz; B Stein
Journal:  J Pharmacol Exp Ther       Date:  1990-09       Impact factor: 4.030

9.  Cellular distribution of phosphodiesterase isoforms in rat cardiac tissue.

Authors:  D C Bode; J R Kanter; L L Brunton
Journal:  Circ Res       Date:  1991-04       Impact factor: 17.367

10.  Cellular distribution and pharmacological sensitivity of low Km cyclic nucleotide phosphodiesterase isozymes in human cardiac muscle from normal and cardiomyopathic subjects.

Authors:  P J Silver; P Allen; J H Etzler; L T Hamel; R G Bentley; E D Pagani
Journal:  Second Messengers Phosphoproteins       Date:  1990
View more
  9 in total

1.  The cardiac IKs potassium channel macromolecular complex includes the phosphodiesterase PDE4D3.

Authors:  Cecile Terrenoire; Miles D Houslay; George S Baillie; Robert S Kass
Journal:  J Biol Chem       Date:  2009-02-13       Impact factor: 5.157

2.  Compartmentation of cAMP signaling in cardiac myocytes: a computational study.

Authors:  Radu V Iancu; Stephen W Jones; Robert D Harvey
Journal:  Biophys J       Date:  2007-02-09       Impact factor: 4.033

3.  Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.

Authors:  Claire Y Zhao; Joseph L Greenstein; Raimond L Winslow
Journal:  J Mol Cell Cardiol       Date:  2015-09-23       Impact factor: 5.000

4.  cAMP microdomains and L-type Ca2+ channel regulation in guinea-pig ventricular myocytes.

Authors:  Sunita Warrier; Gopalakrishnan Ramamurthy; Richard L Eckert; Viacheslav O Nikolaev; Martin J Lohse; Robert D Harvey
Journal:  J Physiol       Date:  2007-02-08       Impact factor: 5.182

5.  Roles of phosphodiesterases in the regulation of the cardiac cyclic nucleotide cross-talk signaling network.

Authors:  Claire Y Zhao; Joseph L Greenstein; Raimond L Winslow
Journal:  J Mol Cell Cardiol       Date:  2016-01-07       Impact factor: 5.000

6.  Low concentrations of UD-CG 212 enhance myocyte contractility by an increase in calcium responsiveness in the presence of inorganic phosphate.

Authors:  J C van Meel; N Redemann; W Diederen; R M Haigh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-06       Impact factor: 3.000

Review 7.  Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics.

Authors:  Emily J Tsai; David A Kass
Journal:  Pharmacol Ther       Date:  2009-03-21       Impact factor: 12.310

8.  Blinded Contractility Analysis in hiPSC-Cardiomyocytes in Engineered Heart Tissue Format: Comparison With Human Atrial Trabeculae.

Authors:  Ingra Mannhardt; Alexandra Eder; Berengere Dumotier; Maksymilian Prondzynski; Elisabeth Krämer; Martin Traebert; Klaus-Dieter Söhren; Frederik Flenner; Konstantina Stathopoulou; Marc D Lemoine; Lucie Carrier; Torsten Christ; Thomas Eschenhagen; Arne Hansen
Journal:  Toxicol Sci       Date:  2017-07-01       Impact factor: 4.849

9.  Experimental and mathematical analysis of cAMP nanodomains.

Authors:  Christian Lohse; Andreas Bock; Isabella Maiellaro; Annette Hannawacker; Lothar R Schad; Martin J Lohse; Wolfgang R Bauer
Journal:  PLoS One       Date:  2017-04-13       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.